Nama's AI scorecard currently rates Recursion Pharmaceuticals Sell (3.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does RXRX report earnings?

Recursion Pharmaceuticals's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.22.

What is the RXRX price target?

The median analyst price target from 6 analysts is $7.00, with a range of $4.00 – $10.00.

Is RXRX Shariah compliant?

Nama's AAOIFI-style screen reads Recursion Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Recursion Pharmaceuticals (RXRX)

Healthcare · Biotechnology · NASDAQ

Recursion Pharmaceuticals (RXRX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.19B and a free-cash-flow yield of -24.1%. Over the most recent reported fiscal year, revenue grew 27.0%. Nama's AI scorecard rates it Sell, 3.6 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.6/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -7.6% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-83.4%

How far the last close sits under the highest price of the past five years.

Market cap	$2.19B
Trailing P/E	—
Price / book	2.1
Price / sales	39.1
FCF yield	-24.1%
Dividend yield	—
Gross margin	1.8%
Operating margin	-1008.6%
Net margin	-962.0%
Revenue growth (YoY)	+27.0%
Revenue growth (3-yr annual)	+23.2%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

RXRX earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate -$0.22). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	-$0.22	-$0.23	+4.3%	$18.05M
Q2 2026	Aug 5, 2026	-$0.25	-$0.23	-8.7%	$7.30M
Q1 2026	May 6, 2026	-$0.22	-$0.26	+15.4%	$6.30M
Q4 2025	Feb 25, 2026	-$0.21	-$0.32	+34.4%	$35.35M

RXRX analyst price target

Median target $7.00 from 6 analysts, ranging $4.00 – $10.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live RXRX data on Nama Insights →

RXRX FAQ

Is RXRX a buy?: Nama's AI scorecard currently rates Recursion Pharmaceuticals Sell (3.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does RXRX report earnings?: Recursion Pharmaceuticals's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.22.
What is the RXRX price target?: The median analyst price target from 6 analysts is $7.00, with a range of $4.00 – $10.00.
Is RXRX Shariah compliant?: Nama's AAOIFI-style screen reads Recursion Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.